Nel ASA's Q3 2026: PEM Surges 65% While Group Revenue Falls 63% — The Execution Gap in Focus

Nel ASA's third-quarter 2026 report, released Thursday, lays out a company pulled in two directions at once. Revenue from customer contracts dropped 63% year-on-year to NOK 112 million, yet the PEM segment expanded briskly and the order intake climbed sharply. For investors, the central question is no longer whether demand exists — it is whether that demand can be converted into revenue and, ultimately, into a better bottom line.

The headline figures are unforgiving. Revenue and other income combined reached NOK 138 million, a distinction worth keeping in mind: that aggregate figure is not the same as customer-contract revenue, which is the measure that captures the collapse in the core business. EBITDA came in at NOK -93 million, and the net loss for the quarter stood at NOK -141 million. The pressure, in other words, is not confined to the top line — both operating result and net result were negative.

A Tale of Two Segments

The composition of the business matters more than the direction of any single metric. PEM revenue rose 65% to NOK 89 million in the third quarter of 2026, a genuine bright spot. Alkaline electrolyser revenue, by contrast, fell 91% to NOK 23 million. A growing PEM business and a negative EBITDA are not mutually exclusive, and the quarter demonstrates exactly that.

Whether PEM can durably offset the alkaline slump is the pivot on which the investment case turns. Growth in one segment improves the outlook; whether it is sufficient to compensate for weakness elsewhere can only be judged by revenue. On that test, the group still has ground to make up.

Orders Tell a Different Story Than the P&L

Contractually booked business presents a far healthier picture. Order intake reached NOK 253 million, up 339%, while the order backlog rose 34% to NOK 1.314 million. PEM order intake was the engine behind that surge, climbing 473% to NOK 245 million. At quarter-end, Nel held liquid assets of NOK 1.078 million.

These figures describe a different stage of the business than reported revenue does. They point to future activity and answer a different question than the income statement — but on their own they do not prove an improvement in profitability. A larger backlog opens up revenue potential without saying anything about a near-term earnings turnaround, and liquidity is a financial stock, not evidence that Nel has reached a self-sustaining operation.

The US Contract: Concrete, but Dated 2027

One tangible data point arrived Tuesday, when Nel disclosed an order worth roughly USD 12 million for its US subsidiary. Nel Hydrogen US will supply several containerised PEM electrolysers from the MC series, along with associated services, to an unnamed global US technology company. Delivery is expected in 2027.

That is a firm purchase order, not a letter of intent — but the delivery horizon explains why it cannot be read as a response to the weakness already booked in the quarter. For the bull case, the order's value lies less in the signature than in the execution; it offers a concrete delivery timeline but must not be treated as revenue already realised.

Rheinmetall: A Feasibility Study, Not a Purchase Order

A separate announcement Tuesday requires different handling altogether. Nel and Rheinmetall intend to examine the technical and commercial feasibility of decentralised production of synthetic fuels based on renewable hydrogen, including possible sites and pilot projects. The agreement is non-binding and constitutes no firm purchase order.

Keeping these categories apart is essential. Financial results show realised performance, orders show contractually captured business, and feasibility studies show possible additional opportunities. An investor who separates the three can weigh the prospects without booking project potential as economic success ahead of time.

What Would Confirm a Turnaround

Sustained PEM growth paired with orders converting into revenue would keep an operating recovery plausible. Should that momentum weaken, or should the alkaline business remain dominant in its decline, the foundation of that scenario would grow more fragile. The risk is a stretch in which PEM keeps expanding without adequately offsetting the alkaline downturn — better order numbers coinciding with weak group revenue and further operating losses. That is precisely why it would be premature to read the higher intake as a completed turnaround.

The delivery of the US order, expected in 2027, is the concrete milestone to watch. Its execution could show whether Nel can turn order-book success into business. Until then, PEM revenue remains the key touchstone: what counts is not the size of the order promise alone, but its economic realisation.